Contineum Therapeutics, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Contineum announced that the MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 for major depressive disorder failed to meet its primary efficacy endpoint—improvement from baseline in MADRS total score at Day 5 versus placebo. The drug was well-tolerated with no new safety signals. Johnson & Johnson, which licensed PIPE-307 globally from Contineum, is evaluating prespecified exploratory endpoints and assessing next steps.
Why this rating
Largest pipeline asset licensed to J&J failed key efficacy milestone. Meaningful portion of company value at risk; PIPE-307 was significant revenue/validation hope. Outcome materially reduces near-term optionality.
Price action (we called it negative)
before filing · preread $11.99 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.